Find Faculty
Sacha Gnjatic, PhD
img_Sacha Gnjatic
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Pathology, Molecular and Cell Based Medicine
PROFESSOR | Oncological Sciences
email
Research Topics
Anti-Tumor Therapy, Antigen Presentation, B Cells, Cancer, Cellular Immunity, Dendritic Cells, Immunological Tolerance, Immunology, Immunosuppression, Lung, Microarray, Proteomics, T Cells, Tolerance, Translation, Vaccine Development
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]
Antigen-specific spontaneous and immunotherapy-induced tumor immunity:
Characterization of serological and cellular immune responses against tumor antigens such as NY-ESO-1, MAGE-A3, or p53, and for their capacity to induce immune responses both spontaneously and in the setting of cancer immunotherapy.
Immune monitoring to discover mechanisms and biomarker of cancer immunotherapies:
Multiscale (host, circulation, tissues, single cell), multiomics (immunophenotyping, immunopathology, immunotranscriptomics, bioinformatics) approaches for biomarker discovery and understanding of mechanisms contributing to clinical responses, adverse events, or primary and acquired resistance to tumor immunotherapies.
Mechanisms of antigen presentation to T cells:
Mechanisms of antigen presentation to and recognition by T cells, including defining epitopes, evaluating viral, bacterial, and parasitic vectors, cross-presentation of antigen to HLA class I, and endogenous antigen presentation to HLA class II.
Inflammatory diseases:
Role of GM-CSF autoantibodies throughout Crohn's disease development. Dissecting role of cytokines, antibody and T cell responses in COVID-19 patients after infection or vaccination.
Tissue immune microenvironment:
Assessment of the tumor microenvironment for immunocytes and suppressive signals, including development of novel spatial technologies to address in depth biomarkers at the tissue site.
Impact of immunoregulation on tumor antigen-specific responses:
Impact of immunoregulation on tumor antigen-specific responses, from co-inhibitory molecules expressed on T cells at the tumor site to the effect of regulatory T cells on anti-tumor effectors, and study of immune tolerance.

BSc3, University College London

MSc, Institut Pasteur

Undergraduate, Ecole Normale Supérieure

PhD, University Paris VII

Post-doc, Memorial Sloan-Kettering - Ludwig Institute

238
Publications

Selected Publications

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial. Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose, Edgar Gonzalez-Kozlova, Mary W. Redman, Hong Chen, Ganiraju C. Manyam, Gayatri Kumar, Jianhua Zhang, Xingzhi Song, Rossana Lazcano, Mario L. Marques-Piubelli, Caddie Laberiano-Fernandez, Frank Rojas, Baili Zhang, Len Taing, Aashna Jhaveri, Jacob Geisberg, Jennifer Altreuter, Franziska Michor, James Provencher, Joyce Yu, Ethan Cerami, Radim Moravec, Kasthuri Kannan, Rajyalakshmi Luthra, Gheath Alatrash, Hsin Hui Huang, Hui Xie, Manishkumar Patel, Kai Nie, Jocelyn Harris, Kimberly Argueta, James Lindsay, Roshni Biswas, Stephen Van Nostrand, Seunghee Kim-Schulze, Jhanelle E. Gray, Roy S. Herbst, Ignacio I. Wistuba, Scott Gettinger, Karen Kelly, Lyudmila Bazhenova, Sacha Gnjatic, J. Jack Lee, Jianjun Zhang, Cara Haymaker. Clinical Cancer Research

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma. David G. Coffey, Keren Osman, Adolfo Aleman, Selma Bekri, Simone Kats, Amishi Dhadwal, Donna Catamero, Seunghee Kim-Schulze, Sacha Gnjatic, Ajai Chari, Samir Parekh, Sundar Jagannath, Hearn Jay Cho. Journal for ImmunoTherapy of Cancer

Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial(Nature Medicine, 10.1038/s41591-023-02568-1). Matthew D. Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin G. Chan, Sara Lewis, Bassam El Achkar, Tanya B. Dorff, Jeremy Paul Cetnar, Brock O. Neil, Anishka D’Souza, Ronac Mamtani, Christos Kyriakopoulos, Tomi Jun, Mahalya Gogerly-Moragoda, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Amir Horowitz, Yayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou, Rafael Cabal, Diane M. Del Valle, G. Kenneth Haines, Li Wang, Kent W. Mouw, Robert M. Samstein, Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim-Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John Sfakianos, Sumanta K. Pal. Nature Medicine

View All Publications

Hess CSM Building Floor 5 Room 105

1470 Madison Ave

New York, NY 10029

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Gnjatic during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Taiho Oncology, Inc
  • Memorial Sloan-Kettering Cancer Center
  • National Cancer Institute/NIH/DHHS
  • Society for Immunotherapy of Cancer

Editorial Services

  • Cancer Immunology Research
  • Frontiers in Immunology

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.